GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer
GeneDx (Nasdaq: WGS) has appointed Bryan Dechairo as Chief Operating Officer, effective immediately. In this newly created role, Dechairo will report to CEO Katherine Stueland and oversee Product & Technology, Operations, Medical Affairs, Innovation, and Program Management teams.
Dechairo brings over 30 years of experience in diagnostic businesses and most recently served as President and CEO of Sherlock Biosciences. He holds a PhD in Human Genetics from University College London and has held executive roles at companies including Pfizer, Myriad Genetics, Assurex, and Medco Health.
The appointment aims to drive operational excellence as GeneDx enters its next phase of commercial growth. The company specializes in pediatric genetics and focuses on delivering personalized health insights for diagnosis, treatment direction, and drug discovery through genomic testing and interpretation services.
GeneDx (Nasdaq: WGS) ha nominato Bryan Dechairo come Chief Operating Officer, con effetto immediato. In questo nuovo ruolo, Dechairo riferirà al CEO Katherine Stueland e supervisionerà i team di Prodotto e Tecnologia, Operazioni, Affari Medici, Innovazione e Gestione dei Programmi.
Dechairo porta con sé oltre 30 anni di esperienza nel settore diagnostico e recentemente ha ricoperto il ruolo di Presidente e CEO di Sherlock Biosciences. Ha conseguito un dottorato in Genetica Umana presso l'University College London e ha ricoperto ruoli dirigenziali in aziende come Pfizer, Myriad Genetics, Assurex e Medco Health.
Questa nomina mira a promuovere l'eccellenza operativa mentre GeneDx entra nella sua prossima fase di crescita commerciale. L'azienda si specializza in genetica pediatrica e si concentra sulla fornitura di informazioni sanitarie personalizzate per la diagnosi, la direzione del trattamento e la scoperta di farmaci attraverso servizi di test e interpretazione genomica.
GeneDx (Nasdaq: WGS) ha nombrado a Bryan Dechairo como Director de Operaciones, con efecto inmediato. En este nuevo rol, Dechairo reportará a la CEO Katherine Stueland y supervisará los equipos de Producto y Tecnología, Operaciones, Asuntos Médicos, Innovación y Gestión de Programas.
Dechairo aporta más de 30 años de experiencia en el sector diagnóstico y, más recientemente, se desempeñó como Presidente y CEO de Sherlock Biosciences. Posee un doctorado en Genética Humana por el University College London y ha ocupado roles ejecutivos en empresas como Pfizer, Myriad Genetics, Assurex y Medco Health.
La nominación tiene como objetivo impulsar la excelencia operativa a medida que GeneDx entra en su próxima fase de crecimiento comercial. La empresa se especializa en genética pediátrica y se enfoca en ofrecer información de salud personalizada para diagnóstico, dirección de tratamiento y descubrimiento de medicamentos a través de servicios de pruebas e interpretación genómicas.
GeneDx (Nasdaq: WGS)가 Bryan Dechairo를 COO(최고 운영 책임자)로 즉시 임명했습니다. 이 새로 창설된 역할에서 Dechairo는 CEO Katherine Stueland에게 보고하며 제품 및 기술, 운영, 의료 업무, 혁신 및 프로그램 관리 팀을 감독하게 됩니다.
Dechairo는 진단 비즈니스에서 30년 이상의 경험을 보유하고 있으며, 최근에는 Sherlock Biosciences의 회장 겸 CEO로 재직했습니다. 그는 런던 대학교에서 인간 유전학 박사 학위를 취득했으며, Pfizer, Myriad Genetics, Assurex 및 Medco Health와 같은 회사에서 경영진 역할을 맡았습니다.
이번 임명은 GeneDx가 상업적 성장의 다음 단계에 진입함에 따라 운영 우수성을 추진하는 것을 목표로 합니다. 이 회사는 소아 유전학을 전문으로 하며, 유전자 검사 및 해석 서비스를 통해 진단, 치료 방향 및 약물 발견을 위한 개인화된 건강 인사이트를 제공하는 데 중점을 두고 있습니다.
GeneDx (Nasdaq: WGS) a nommé Bryan Dechairo comme Directeur des opérations, avec effet immédiat. Dans ce nouveau rôle, Dechairo rendra compte à la PDG Katherine Stueland et supervisera les équipes Produit & Technologie, Opérations, Affaires médicales, Innovation et Gestion de programmes.
Dechairo apporte plus de 30 ans d'expérience dans le secteur du diagnostic et a récemment occupé le poste de Président et PDG de Sherlock Biosciences. Il détient un doctorat en Génétique Humaine de l'University College London et a occupé des postes de direction dans des entreprises telles que Pfizer, Myriad Genetics, Assurex et Medco Health.
Cette nomination vise à promouvoir l'excellence opérationnelle alors que GeneDx entre dans sa prochaine phase de croissance commerciale. L'entreprise se spécialise en génétique pédiatrique et se concentre sur la fourniture d'informations sanitaires personnalisées pour le diagnostic, les orientations de traitement et la découverte de médicaments grâce à des services de tests et d'interprétation génomique.
GeneDx (Nasdaq: WGS) hat Bryan Dechairo mit sofortiger Wirkung zum Chief Operating Officer ernannt. In dieser neu geschaffenen Rolle wird Dechairo an CEO Katherine Stueland berichten und die Teams für Produkt & Technologie, Betrieb, Medizinische Angelegenheiten, Innovation und Programmmanagement leiten.
Dechairo bringt über 30 Jahre Erfahrung im Diagnosegeschäft mit und war zuletzt Präsident und CEO von Sherlock Biosciences. Er hat einen Doktortitel in Humaner Genetik vom University College London und bekleidete Führungspositionen in Unternehmen wie Pfizer, Myriad Genetics, Assurex und Medco Health.
Die Ernennung zielt darauf ab, die operative Exzellenz voranzutreiben, während GeneDx in die nächste Phase des kommerziellen Wachstums eintritt. Das Unternehmen ist auf Pädiatrische Genetik spezialisiert und konzentriert sich darauf, personalisierte Gesundheitsinformationen für Diagnose, Behandlungsrichtlinien und Arzneimittelentdeckung durch genomische Test- und Interpretationsdienste bereitzustellen.
- Creation of new COO position indicates company's focus on operational scaling
- Appointment of experienced executive with 30+ years in diagnostics industry
- Strategic move towards accelerating commercial growth phase
- None.
Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs, Innovation and More
New Executive Leadership Positions Company for Growth and Scale
As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the Program Management teams at GeneDx. He will be pivotal in driving operational excellence as the company enters the next phase of commercial growth.
“Bryan’s extensive clinical, technical and operational experience and proven ability to lead scalable transformations will play a pivotal role in helping us execute our strategic vision and accelerate the adoption of genomic insights across healthcare,” said Stueland. “As we embark on the next phase of our growth and scale, I am confident Bryan’s leadership will be critical in helping us deliver impactful genomic insights and improve health outcomes for an ever-growing number of patients and families.”
Bryan brings over 30 years of experience in exploratory and commercial diagnostic businesses, driving the development of revenue-generating clinical innovations that enhance patient outcomes. He most recently served as President and CEO of Sherlock Biosciences, where he successfully transformed the company from a research-stage start-up into a commercial operation. Bryan has also held executive leadership roles at prominent diagnostic and pharmaceutical companies, including Pfizer, Myriad Genetics, Assurex, Medco Health and others. Bryan holds a PhD in Human Genetics from the University College of
“GeneDx has built a market-leading position in pediatric genetics and has an incredible opportunity to pave the way for the genomics revolution in healthcare today,” said Dechairo. “With world-class products, advanced AI and the most dynamic minds in the industry, I’m looking forward to supercharging operational excellence to accelerate profitable growth.”
About GeneDx:
GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation services, fueled by the world’s largest, rare disease data sets. For more information, please visit www.genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250102377634/en/
Press@genedx.com
Investors@genedx.com
Source: GeneDx
FAQ
What role will Bryan Dechairo have at GeneDx (WGS) and what will he oversee?
What is Bryan Dechairo's professional background before joining GeneDx (WGS)?
How does Bryan Dechairo's appointment align with GeneDx's (WGS) growth strategy?
What are GeneDx's (WGS) main business focus areas?
